Molecular Therapy: Nucleic Acids, 2020 Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated.
Yutang Huang +7 more
doaj +3 more sources
CEMIP promotes gefitinib resistance in lung cancer with EGFR-mutation possibly through forming a stable complex CEMIP/c-MYC [PDF]
BBA AdvancesWhile gefitinib greatly improves the prognosis of lung cancer patients with epidermal growth factor receptor (EGFR) mutation, its inevitable resistance severely diminishes therapeutic efficacy.
Li Li +11 more
doaj +2 more sources
Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells [PDF]
Communications BiologyInevitable gefitinib resistance is the biggest bottleneck in current treatment and the mechanisms are not fully understood. Here, we observe that PFTK1 (also named CDK14) is significantly enhanced in NSCLC with gefitinib resistance.
Xiaoting Jia +9 more
doaj +2 more sources
NEAT1_1 confers gefitinib resistance in lung adenocarcinoma through promoting AKR1C1-mediated ferroptosis defence [PDF]
Cell Death DiscoveryGefitinib is one of the most extensively utilized epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for treating advanced lung adenocarcinoma (LUAD) patients harboring EGFR mutation.
Shuman Zhen +12 more
doaj +2 more sources
LncRNA AFAP1-AS1 Induces Gefitinib Resistance of Lung Adenocarcinoma Through the miR-653-5p/AGR2 Axis [PDF]
Therapeutics and Clinical Risk Management, 2023 Tao Zuo,1,* Ping Jiang,2,* Jun Fu,1 Yongjian Zhang1 1Department of Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Department of ...
Zuo T, Jiang P, Fu J, Zhang Y
doaj +2 more sources
Chinese Journal of Lung Cancer, 2015 Background and objective Nowadays the secondary resistance of gefitinib in the treatment of lung adenocarcinoma is an outstanding problem. This research is to explore whether the gefitinib secondary resistance can be induced by gefitinib, to explore ...
Qilong WANG, Min LI, Chengping HU
doaj +2 more sources
Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells [PDF]
Applied Sciences, 2021 Gefitinib has been clinically demonstrated to be effective in the first-line setting for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).
Shuang Zhao +3 more
doaj +2 more sources
Exosome-derived circKIF20B suppresses gefitinib resistance and cell proliferation in non-small cell lung cancer [PDF]
Cancer Cell International, 2023 Background The gefitinib resistance mechanism in non-small cell lung cancer (NSCLC) remains unclear, albeit exosomal circular RNA (circRNA) is known to possibly play a vital role in it.
Si-Liang Wei +7 more
doaj +2 more sources
USP22 promotes gefitinib resistance and inhibits ferroptosis in non‐small cell lung cancer by deubiquitination of MDM2 [PDF]
Thoracic CancerBackground The emergence of chemoresistance markedly compromised the treatment efficiency of human cancer, including non‐small cell lung cancer (NSCLC). In the present study, we aimed to explore the effects of ubiquitin‐specific peptidase 22 (USP22) and ...
Peng Lu, Zhaoguo Li, Hang Xu
doaj +2 more sources
Cancer Research, 2010 Molecular targeted agents are being a mainstay in non-small cell lung cancer. Dramatic responses to the epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitor (TKI) are observed in advanced non-small cell lung cancer (NSCLC), especially with ...
Eiki Ichihara +10 more
core +2 more sources